House committee presses FDA center directors on domestic manufacturing, LDTs

The House En­er­gy & Com­merce’s sub­com­mit­tee on health heard from the di­rec­tors of the FDA’s de­vice, bi­o­log­ics and drug cen­ters on Wednes­day for a “check up.” Rep­re­sen­ta­tives pep­pered the of­fi­cials on top­ics rang­ing from gener­ic drug man­u­fac­tur­ing to the agency’s new rule on lab-de­vel­oped tests.

Com­mit­tee Chair Cathy Mc­Mor­ris Rodgers (R-WA) ques­tioned FDA drug cen­ter di­rec­tor Pa­trizia Cavaz­zoni about on-shoring and near-shoring drug man­u­fac­tur­ing. Rodgers said that the FDA is some­times an “im­ped­i­ment” to in­cen­tiviz­ing man­u­fac­tur­ing in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.